VanEck Pharmaceutical ETF (PPH) Research
The VanEck Pharmaceutical ETF (PPH) endeavors to match, before any charges or costs, the price and income returns of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR) as precisely as feasible. This benchmark is constructed to reflect the comprehensive performance of businesses operating within the pharmaceutical sector, covering their activities from drug discovery and development to manufacturing, promotion, and distribution.
Market snapshot
- Symbol
- PPH
- Price
- $102.53
- Day change
- -1.64%
- Market cap
- $605.4M
- 52-week range
- 81.74-112.58
- Sector
- Financial Services
- Industry
- Asset Management
Recent news
- Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Peer companies
- VanEck Biotech ETF (BBH)
- BNY Mellon US Mid Cap Core Equity ETF (BKMC)
- WisdomTree China ex-State-Owned Enterprises Fund (CXSE)
- Longview Advantage ETF (EBI)
- First Trust Small Cap Growth AlphaDEX Fund (FYC)
- iShares U.S. Pharmaceuticals ETF (IHE)
- Range Nuclear Renaissance Index ETF (NUKZ)
- Harbor International Compounders ETF (OSEA) (OSEA)
Open VanEck Pharmaceutical ETF (PPH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.